var data={"title":"Cefdinir: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Cefdinir: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5836?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=cefdinir-drug-information\" class=\"drug drug_general\">see &quot;Cefdinir: Drug information&quot;</a> and <a href=\"topic.htm?path=cefdinir-patient-drug-information\" class=\"drug drug_patient\">see &quot;Cefdinir: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045906\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Cephalosporin (Third Generation)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045898\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=cefdinir-drug-information\" class=\"drug drug_general\">see &quot;Cefdinir: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> 2012): Mild to moderate infections: Infants, Children, and Adolescents: Oral: 14 mg/kg/day in divided doses 1 to 2 times daily; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bronchitis, acute exacerbation:</b> Oral: Adolescents: 300 mg every 12 hours for 5 to 10 days <b>or</b> 600 mg every 24 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Otitis media, acute:</b> Infants &ge;6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours for 5 to 10 days; maximum daily dose: 600 mg/<b>day</b>. Variable duration of therapy: If &lt;2 years of age or severe symptoms (any age): 10-day course; if 2 to 5 years of age with mild to moderate symptoms: 7-day course; if &ge;6 years of age with mild to moderate symptoms: 5- to 7-day course (AAP [Lieberthal 2013]). <b>Note:</b> Recommended by the AAP as an alternative agent for initial treatment in penicillin allergic patients (AAP [Lieberthal 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pharyngitis/Tonsillitis: Note:</b> Although FDA approved at twice daily dosing, duration &lt;10 days is not recommended (Shulman 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children: Oral: 7 mg/kg/dose every 12 hours for 5 to 10 days <b>or</b> 14 mg/kg/dose every 24 hours for 10 days; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 300 mg every 12 hours for 5 to 10 days <b>or</b> 600 mg every 24 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia, community-acquired:</b> Adolescents: Oral: 300 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infection, uncomplicated: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children: Oral: 14 mg/kg/day in divided doses twice daily for 10 days; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 300 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sinusitis, acute maxillary: Note:</b> Due to decreased <i>S. pneumonia</i> sensitivity, cefdinir is no longer recommended as monotherapy for the initial empiric treatment of sinusitis (Chow 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months and Children: Oral: 14 mg/kg/day in divided doses every 12 to 24 hours for 10 days; maximum daily dose: 600 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Oral: 300 mg every 12 hours <b>or</b> 600 mg every 24 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Bronchitis, acute exacerbation:</b> Oral: 300 mg every 12 hours for 5 to 10 days <b>or</b> 600 mg once daily for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pharyngitis/tonsillitis:</b> Oral: 300 mg every 12 hours for 5 to 10 days <b>or</b> 600 mg once daily for 10 days. <b>Note:</b> Although FDA approved at twice daily dosing, duration &lt;10 days is not recommended (Shulman 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pneumonia, community-acquired:</b> Oral: 300 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Sinusitis, acute maxillary:</b> Oral: 300 mg every 12 hours <b>or</b> 600 mg once daily for 10 days. <b>Note:</b> Due to decreased <i>S. pneumonia</i> sensitivity, cefdinir is no longer recommended as monotherapy for the initial empiric treatment of sinusitis (Chow 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Skin and skin structure infection (uncomplicated):</b> Oral: 300 mg every 12 hours for 10 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants &ge;6 months and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute/1.73 m<sup>2</sup>: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: 7 mg/kg/dose once daily; maximum daily dose: 300 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: 300 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Dialyzable (63%): Infants &ge;6 months, Children, Adolescents, and Adults: Initial dose: 7 mg/kg/dose (maximum dose: 300 mg) every other day. At the conclusion of each hemodialysis session, an additional dose (7 mg/kg/dose up to 300 mg) should be given. Subsequent doses should be administered every other day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosing adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147161\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 125 mg/5 mL (60 mL, 100 mL); 250 mg/5 mL (60 mL, 100 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147146\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045909\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May administer with or without food; administer with food if stomach upset occurs; administer cefdinir at least 2 hours before or after antacids or iron supplements; shake suspension well before use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147175\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Store reconstituted suspension at room temperature 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) for 10 days.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045908\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment  of susceptible acute bacterial otitis media (FDA approved in ages 6 months to 12 years); treatment of susceptible acute maxillary sinusitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections (FDA approved in ages &ge;6 months and adults); treatment of susceptible  acute exacerbations of chronic bronchitis  and community-acquired pneumonia (FDA approved in adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147202\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased serum bicarbonate, glycosuria, hyperglycemia, hyperphosphatemia, increased gamma-glutamyl transferase, increased lactate dehydrogenase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria, occult blood in urine, urine abnormality (increased leukocytes), urine alkalinization, vaginitis, vulvovaginal candidiasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic: Abnormal neutrophils (functional disorder of polymorphonuclear neutrophils), change in WBC count, eosinophilia, lymphocytopenia, lymphocytosis, thrombocythemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum alkaline phosphatase, increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased urine specific gravity</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abnormal stools, anaphylaxis, anorexia, asthma, blood coagulation disorder, bloody diarrhea, candidiasis, cardiac failure, chest pain, cholestasis, conjunctivitis, constipation, cutaneous candidiasis, decreased hemoglobin, decreased urine specific gravity, disseminated intravascular coagulation, dizziness, drowsiness, dyspepsia, enterocolitis (acute), eosinophilic pneumonitis, erythema multiforme, erythema nodosum, exfoliative dermatitis, facial edema, fever, flatulence, fulminant hepatitis, granulocytopenia, hemolytic anemia, hemorrhagic colitis, hemorrhagic diathesis, hepatic failure, hepatitis (acute), hyperkalemia, hyperkinesia, hypersensitivity angiitis, hypertension, hypocalcemia, hypophosphatemia, immune thrombocytopenia, increased amylase, increased blood urea nitrogen, increased monocytes, increased serum AST, increased serum bilirubin, insomnia, interstitial pneumonitis (idiopathic), intestinal obstruction, involuntary body movements, jaundice, laryngeal edema, leukopenia, leukorrhea, loss of consciousness, maculopapular rash, melena, myocardial infarction, pancytopenia, peptic ulcer, pneumonia (drug-induced), pruritus, pseudomembranous colitis, renal disease, renal failure (acute), respiratory failure (acute), rhabdomyolysis, serum sickness, shock, Stevens-Johnson syndrome, stomatitis, thrombocytopenia, toxic epidermal necrolysis, upper gastrointestinal hemorrhage, weakness, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147166\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cefdinir, any component of the formulation, or other cephalosporins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147150\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Colitis: Use with caution in patients with a history of colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;30 mL/minute); dosage adjustment may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Iron-containing products: Cases of reddish stools have been reported with concomitant use of cefdinir and iron-containing products due to the formation of a nonabsorbable complex in the GI tract.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46105124\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Iron-containing infant formulas do not affect the pharmacokinetics of cefdinir but may result in the development of red-appearing, nonbloody stools; this occurs when cefdinir is coadministered with iron-containing products and an insoluble iron-cefdinir complex forms; patients/parents should be counseled. Administer cautiously to penicillin-sensitive patients, especially IgE-mediated reactions (eg, anaphylaxis, urticaria). Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Use with caution in patients with a history of colitis. Use caution with renal dysfunction (CrCl &lt;30 mL/minute); dose adjustment may be required. Potentially significant drug-drug interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298986\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147155\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13125&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Cephalosporins (3rd Generation) may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iron Salts: May decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.<b> Exceptions: </b>Ferric Carboxymaltose; Ferric Gluconate; Ferric Hydroxide Polymaltose Complex; Ferric Pyrophosphate Citrate; Ferumoxytol; Iron Dextran Complex; Iron Isomaltoside; Iron Sucrose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Cefdinir. Specifically, Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex. Management: Avoid concurrent cefdinir and oral iron-containing multivitamins when possible. Separating doses by several hours may minimize interaction. Iron-containing infant formulas do not appear to interact with cefdinir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Cephalosporins.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147157\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F854704\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic events have not been observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045905\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluate renal function before and during therapy; with prolonged therapy, monitor coagulation tests, CBC, liver function test periodically, and number and type of stools/day for diarrhea. Observe for signs and symptoms of anaphylaxis during first dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147149\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147165\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Penetrates into blister fluid, middle ear fluid, tonsils, sinus, and lung tissues; V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 6 months to 12 years: 0.67 &plusmn; 0.38 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.35 &plusmn; 0.29 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 60% to 70% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Minimal</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Capsule: 16% to 21%; suspension 25% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1.7 (&plusmn; 0.6) hours with normal renal function  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine (~12% to 18% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147168\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Cefdinir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (60): $306.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Cefdinir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">125 mg/5 mL (60 mL): $51.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/5 mL (60 mL): $99.48</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F147169\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adcef (IN);</li>\n      <li>Addcef (VN);</li>\n      <li>Adinir (BD);</li>\n      <li>Anicef (KR);</li>\n      <li>Anycef (KR);</li>\n      <li>Cednir (BD);</li>\n      <li>Cefdiar (KR);</li>\n      <li>Cefnaxl (PH);</li>\n      <li>Cefnir (BD, PK);</li>\n      <li>Cefralin (PE);</li>\n      <li>Cefzon (CN, JP);</li>\n      <li>Danircap (VN);</li>\n      <li>Kefnir (MY, VN);</li>\n      <li>Medsidin (VN);</li>\n      <li>Nilocef (BD);</li>\n      <li>Nircef (ID);</li>\n      <li>Nirocef (PH);</li>\n      <li>Omicef (PH);</li>\n      <li>Omnicef (AE, BB, BH, BM, BS, BZ, CY, EG, GY, ID, IL, IQ, IR, JM, JO, KR, KW, LB, LY, NL, OM, PR, QA, SA, SE, SR, SY, TH, TT, VN, YE);</li>\n      <li>Omnicef R (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Orcef-DS (PH);</li>\n      <li>Samnir (TH);</li>\n      <li>Sefdin (IN);</li>\n      <li>Sefdy (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):e25-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefdinir-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cefdinir powder for suspension [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; March 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chow AW, Benninger MS, Brook I, et al, &quot;IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults,&quot; <i>Clin Infect Dis</i>, 2012, 54(8):e72-e112.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefdinir-pediatric-drug-information/abstract-text/22438350/pubmed\" target=\"_blank\" id=\"22438350\">22438350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein JO and McCracken GH Jr, &ldquo;Summary: Role of a New Oral Cephalosporin, Cefdinir, for Therapy of Infections of Infants and Children,&rdquo; <i>Pediatr Infect Dis J</i>, 2000, 19(12 Suppl):S181-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefdinir-pediatric-drug-information/abstract-text/11144402/pubmed\" target=\"_blank\" id=\"11144402\">11144402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lieberthal AS, Carroll AE, Chonmaitree T, et al, &quot;The Diagnosis and Management of Acute Otitis Media,&quot; <i>Pediatrics</i>, 2013, 131(3):e964-99.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefdinir-pediatric-drug-information/abstract-text/23439909/pubmed\" target=\"_blank\" id=\"23439909\">23439909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry CM and Scott LJ, &quot;Cefdinir: A Review of Its Use in the Management of Mild-to-Moderate Bacterial Infections,&quot; <i>Drugs</i>, 2004, 64(13):1433-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/cefdinir-pediatric-drug-information/abstract-text/15212560/pubmed\" target=\"_blank\" id=\"15212560\">15212560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &quot;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&quot; Clin Infect Dis, 2012. Available at http://aapredbook.aappublications.org/cgi/content/full </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/23215911</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13125 Version 153.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045906\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045898\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F147161\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F147146\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045909\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F147175\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045908\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F147202\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F147166\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F147150\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F46105124\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298986\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F147155\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F147157\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F854704\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045905\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F147149\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F147165\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F147168\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F147169\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13125|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=cefdinir-drug-information\" class=\"drug drug_general\">Cefdinir: Drug information</a></li><li><a href=\"topic.htm?path=cefdinir-patient-drug-information\" class=\"drug drug_patient\">Cefdinir: Patient drug information</a></li></ul></div></div>","javascript":null}